A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
ADC Therapeutics is a commercial-stage global pioneer in the field of antibody drug conjugates (“ADCs”). The Company is advancing its proprietary ADC technology with the goal of transforming the cancer treatment paradigm for patients with hematologic malignancies and solid tumors. We have a validated and differentiated technology platform with multiple payloads, linkers and conjugation chemistry, enabling the design of next-generation potent ADCs with an enhanced therapeutic index. We are seeking to expand the label for our FDA-approved and marketed product, ZYNLONTA® (loncastuximab tesirine) into new indications and earlier lines of therapy while pursuing our early-stage solid tumor programs. We leverage our scientific and technical expertise and apply a disciplined approach to target selection to expand and advance our pipeline.
| Metric | TTM | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | 69M | - | - | - |
| Net Income | -167M | -158M | -240M | -157M |
| EPS | $-1.41 | $-1.62 | $-2.94 | $-2.01 |
| Free Cash Flow | -132M | -125M | -122M | -139M |
| ROIC | -37.1% | -32.1% | -37.0% | -83.1% |
| Gross Margin | - | - | - | - |
| Debt/Equity | 0.00 | -0.56 | -0.76 | 1.38 |
| Dividends/Share | $0.00 | - | - | - |
| Operating Income | -136M | -131M | -166M | -123M |
| Operating Margin | -196.6% | - | - | - |
| ROE | 0.0% | - | - | -197.8% |
| Shares Outstanding | 124M | 97M | 82M | 78M |
| Metric | 2022 | |||
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | N/A | N/A | N/A | 69M |
| Gross Margin | N/A | N/A | N/A | N/A |
| R&D | N/A | N/A | N/A | N/A |
| SG&A | N/A | N/A | N/A | N/A |
| EBIT | -123M | -166M | -131M | -136M |
| Op. Margin | N/A | N/A | N/A | -196.6% |
| Net Income | -157M | -240M | -158M | -167M |
| Net Margin | N/A | N/A | N/A | -241.3% |
| Non-Recurring | 0 | 0 | 0 | 0 |
| Returns on Capital | ||||
| ROIC | -83.1% | -37.0% | -32.1% | -37.1% |
| ROE | -197.8% | N/A | N/A | 0.0% |
| ROA | -32.0% | -67.7% | -46.6% | -57.6% |
| Cash Flow | ||||
| Op. Cash Flow | -138M | -119M | -124M | -132M |
| Free Cash Flow | -139M | -122M | -125M | -132M |
| Owner Earnings | -189M | -133M | -132M | -140M |
| CapEx | 687K | 3.2M | 867K | 0 |
| Maint. CapEx | 1.1M | 1.2M | 1.3M | 1.3M |
| Growth CapEx | 0 | 2.0M | 0 | 0 |
| D&A | 1.1M | 1.2M | 1.3M | 1.3M |
| CapEx/OCF | N/A | N/A | N/A | 0.0% |
| Capital Allocation | ||||
| Dividends Paid | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 49M | 13M | 6.6M | 6.6M |
| Debt Repayment | 2.8M | 0 | 0 | 0 |
| Balance Sheet | ||||
| Net Debt | -217M | -166M | -137M | -120M |
| Cash & Equiv. | N/A | N/A | N/A | 235M |
| Long-Term Debt | 110M | 113M | 114M | 114M |
| Debt/Equity | 1.38 | -0.76 | -0.56 | 0.00 |
| Interest Coverage | -3.4 | -3.6 | -2.6 | -2.6 |
| Equity | 79M | -148M | -203M | -238M |
| Total Assets | 491M | 355M | 322M | 290M |
| Total Liabilities | 411M | 503M | 525M | 528M |
| Intangibles | N/A | N/A | N/A | N/A |
| Retained Earnings | -1.1B | -1.3B | -1.5B | -1.5B |
| Working Capital | 353M | 269M | 227M | 227M |
| Current Assets | 435M | 336M | 307M | 307M |
| Current Liabilities | 82M | 68M | 80M | 80M |
| Per Share Data | ||||
| EPS | -2.01 | -2.94 | -1.62 | -1.41 |
| Owner EPS | -2.41 | -1.63 | -1.35 | -1.13 |
| Book Value | 1.02 | -1.82 | -2.08 | -1.92 |
| Cash Flow/Share | -1.77 | -1.45 | -1.27 | -1.34 |
| Dividends/Share | N/A | N/A | N/A | 0.00 |
| Shares Out. | 78.2M | 81.7M | 97.4M | 123.9M |
| Valuation | ||||
| P/E Ratio | N/A | N/A | N/A | -2.7 |
| P/FCF | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A |
| Price/Book | 3.5 | N/A | N/A | N/A |
| Price/Sales | N/A | N/A | N/A | 6.8 |
| FCF Yield | -49.4% | -93.9% | -63.0% | -28.0% |
| Market Cap | 281M | 130M | 198M | 472M |
| Avg. Price | 9.33 | 2.06 | 3.36 | 3.81 |
| Year-End Price | 3.60 | 1.59 | 2.03 | 3.81 |
ADC Therapeutics SA passes 0 of 9 quality checks, indicating weak fundamentals.
ADC Therapeutics SA (ADCT) has a 5-year average return on invested capital (ROIC) of -50.7%. This is below average and may indicate limited pricing power.
ADC Therapeutics SA (ADCT) has a market capitalization of $472M. It is classified as a small-cap stock.
ADC Therapeutics SA (ADCT) does not currently pay a regular dividend.
ADC Therapeutics SA (ADCT) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
ADC Therapeutics SA (ADCT) generated $-125 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
ADC Therapeutics SA (ADCT) reported earnings per share (EPS) of $-1.62 in its most recent fiscal year.
The Ledger Terminal provides 3 years of financial data for ADC Therapeutics SA (ADCT), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
ADC Therapeutics SA (ADCT) has a book value per share of $-2.08, based on its most recent annual SEC filing.